2024-03-08 19:37:17 ET
Summary
- Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients.
- The company is now focused on moving their drug to the first-line setting and has started a clinical trial to evaluate its efficacy.
- Cardiff Oncology has a strong financial position with enough funds to operate through Q3 2025, but the success of their drug is heavily dependent on the outcomes of a single trial.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)